Genomic Assay Predicts Biochemical Failure and Risk of Metastasis in Prostate Cancer Patients After Surgery and Radiation Therapy

The Decipher test uses the expression of these biomarkers to calculate the probability of clinical metastasis within five years of radical prostatectomy surgery and within three years of successive PSA rise (biochemical recurrence).

Results revealed that Decipher correctly predicted biochemical failure and risk of metastasis after prostate cancer postsurgical irradiation. It was suggested that patients with lower risk as defined by Decipher would benefit from delayed radiation treatment, as opposed to those with higher Decipher scores. However, this needs prospective validation in order to become generally accepted. Nonetheless, genomic-based models may be useful for improved decision-making for treatment of high-risk prostate cancer.

"We are moving away from treating everyone the same," said first author Dr. Robert Den, assistant professor of radiation oncology and cancer biology at Thomas Jefferson University. "Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy. Our analysis suggests that genomic analysis scores could be used, in concert with other diagnostic measures such as PSA testing, to help determine which patients would benefit from additional radiation therapy and more aggressive measures, and which are less likely to benefit."

The study was published in the July 8, 2014, online edition of the International Journal of Radiation Oncology*Biology*Physics.

Related Links:
Thomas Jefferson University
GenomeDx Biosciences